Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
24,824
Total Claims
$4.3M
Drug Cost
1,313
Beneficiaries
$3,243
Cost/Patient
Risk Score Breakdown 24/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+219%
Opioid rate vs peers
8.2% vs 2.6% avg
+204%
Cost per patient vs peers
$3,243 vs $1,068 avg
+84%
Brand preference vs peers
16.6% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
Opioid rate is 219% above Family Practice peers. This is a significant deviation that may reflect a specialized patient population or concerning prescribing patterns.
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
8.2%
Opioid Rate
2,041
Opioid Claims
$63K
Opioid Cost
6.3%
Long-Acting Rate
Brand vs Generic
Brand: 4,061 claims · $3.3M
Generic: 20,417 claims · $905K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 207 | $251K |
| Apixaban | 237 | $244K |
| Fluticasone/Umeclidin/Vilanter | 254 | $191K |
| Empagliflozin | 125 | $169K |
| Semaglutide | 91 | $148K |
| Rivaroxaban | 127 | $144K |
| Dulaglutide | 97 | $122K |
| Dapagliflozin Propanediol | 114 | $119K |
| Diclofenac Potassium | 24 | $112K |
| Etanercept | 15 | $110K |
| Insulin Glargine,hum.Rec.Anlog | 97 | $96K |
| Sitagliptin Phosphate | 61 | $84K |
| Metformin Hcl | 15 | $83K |
| Sacubitril/Valsartan | 67 | $80K |
| Tirzepatide | 67 | $78K |
Prescribing Profile
Patient Profile
73
Avg Age
57%
Female
2.01
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data